ARTICLE | Clinical News

Glivec regulatory update

April 23, 2012 7:00 AM UTC

The Scottish Medicines Consortium recommended the restricted use of Novartis' Glivec imatinib on the National Health Service (NHS) in Scotland as adjuvant treatment of adult patients for 36 months following resection of stem cell factor ( SCF) receptor tyrosine kinase (c-Kit; KIT; CD117)-positive gastrointestinal stromal tumors (GIST). The consortium recommended the use of Glivec only in patients at high risk of recurrence following complete resection. The consortium previously accepted Glivec as an adjuvant treatment for 12 months following resection of KIT-positive GIST. ...